Evidence map›Paper›PMID 41174667›Full record

Observational studyJournal of translational medicine2025

A machine learning model including pentraxin-3 as predictor of outcomes in community-acquired pneumonia.

Antonio Voza, Stefano Aliberti, Fabrizio Bonelli, Paolo Ingallinella, Elisa Ghezzi, Chiara Mauro, Clara Rossini, Claudio Mastronardo, Sonia Felotti, Barbara Bottazzi and 4 more

Registry-linked trialAbstract readMulticenter StudyObservational Study
In one paragraph

Observational study in Journal of translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06491004 (Evaluation of DiaSorin LIAISON® PTX3), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06491004 completednot on this map

Evaluation of DiaSorin LIAISON® PTX3 (Long Pentraxin 3) Assay in Patients With Pneumonia

TypeobservationalSponsorDiasorin Italia S.p.A.Ran2021 to 2024Enrolled281ConditionsPneumoniaArmsPTX3 assay
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Antonio Voza *IRCCS Humanitas Research Hospital, Milan, Italy.
Stefano Aliberti *IRCCS Humanitas Research Hospital, Milan, Italy.
Fabrizio BonelliDiasorin SpA, Saluggia, Italy.
Paolo IngallinellaDiasorin Italia SpA, Bresso, Italy.
Elisa GhezziDiasorin Italia SpA, Bresso, Italy.
Chiara MauroDiasorin Italia SpA, Bresso, Italy.
Clara RossiniDiasorin Italia SpA, Bresso, Italy.
Claudio MastronardoReply Data, Milan, Italy.
Sonia FelottiReply Data, Milan, Italy.
Barbara BottazziIRCCS Humanitas Research Hospital, Milan, Italy.
Cecilia GarlandaIRCCS Humanitas Research Hospital, Milan, Italy.
Claudia ZieroldConsultant for DiaSorin, Lugano, Switzerland.
Giorgio GhignoniDiasorin SpA, Saluggia, Italy.
Alberto MantovaniIRCCS Humanitas Research Hospital, Milan, Italy. alberto.mantovaani@humanitasresearch.it.ORCID 0000-0001-5578-236X

Funding

Fondazione AIRC per la ricerca sul cancro ETS 19014Fondazione AIRC per la ricerca sul cancro ETS 21147Fondazione AIRC per la ricerca sul cancro ETS 23465Fondazione AIRC per la ricerca sul cancro ETS awards n° 9962Fondazione AIRC per la ricerca sul cancro ETS Special Program 5x1000
6 · The paper itself

Abstract

backgroundThe clinical diagnosis, severity assessment, and outcome prognostication of community-acquired pneumonia (CAP) remain challenging due to the complex disease pathophysiology. Accurate outcome prediction is crucial for optimizing patient management, reducing mortality, and minimizing hospital and ICU admissions.

methodsIn this prospective observational cohort study, 228 CAP patients with varying degrees of disease severity were assessed. Clinical and demographic data, along with multiple biomarker measurements, including pentraxin-3 (PTX3), were analysed longitudinally. The primary outcome was clinical failure.

resultsAmong the single parameters evaluated, the oxygen saturation to fraction of inspired oxygen ratio (SpO

conclusionsWhile SpO TRIAL REGISTRATION N: NCT06491004 (ClinicalTrials.gov).

Indexed as

Community-Acquired InfectionsC-Reactive ProteinMachine LearningPneumoniaSerum Amyloid P-ComponentAgedArea Under CurveBiomarkersCommunity-Acquired PneumoniaFemaleHumansMaleMiddle AgedPentraxinsPrognosisProspective StudiesBiomarkersC-Reactive ProteinPentraxinsSerum Amyloid P-Component

Identifiers

PMID41174667
PMCPMC12579427

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.